Helius Medical Technologies Inc. has announced an amendment to its 2022 Equity Incentive Plan, as approved by the Board of Directors and stockholders. Effective June 16, 2025, the plan's amendment increases the number of shares of common stock available for issuance by 20%, amounting to 7.1 million shares. This change follows the company's recent public offering closure and aims to adjust the incentive framework for the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.